Immunotherapy Research in Oncology Focuses on Resistance
Research into the mechanisms that promote resistance to immune checkpoint blockade therapies suggests the need for new strategies for patients with immunorefractory disease.
Related Articles
Lymphodepletion Enhances MAR T-Cell Expansion and Persistence in R/R Lymphoma
Lymphodepletion was associated with enhanced MAR T-cell response and antitumor activity with MT-601 in patients with relapsed/refractory lymphoma.
FDA ODAC Votes Against the Applicability of STARGLO Data for Glofitamab Plus Chemo for U.S. Patients With R/R DLBCL
The FDA’s ODAC voted against the applicability of STARGLO trial results to U.S. patients with relapsed/refractory DLBCL.
OncLive – Clinical Oncology News, Cancer Expert Insights
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Acoustic Cluster Therapy Platform Boosts Tumor Shrinkage in Metastatic CRC
The ACTIVATE trial confirmed the safety and enhanced efficacy of Acoustic Cluster Therapy plus chemotherapy in patients with metastatic colorectal cancer.
ctDNA Aids in Elucidating the Role of Select Therapies for CRC
In the colorectal cancer space, the role of ctDNA can help reduce the use of certain therapies.
Experts Preview Key Presentations to Watch in Gynecologic Oncology at ASCO 2025
Experts highlight key abstracts and presentations to keep an eye on in gynecologic oncology at the 2025 ASCO Annual Meeting.
FDA Approval of Perioperative Durvalumab Plus Chemo Supports the Efficacy of a Novel MIBC Management Approach
Matthew Galsky, MD, discusses the significance of the FDA approval of neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in MIBC.
Cetuximab β Plus FOLFIRI Displays Significant Clinical Activity in First-Line mCRC
Cetuximab β was effective and safe in patients with RAS/BRAF wild-type metastatic colorectal cancer.
OncLive Polls Spotlight Phase 3 Breast Cancer Studies Generating Buzz Ahead of ASCO 2025
Breast cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.
5-Year Phase 2 Data Show 0% Recurrence Rate After Surgery Omission in Select Patients With Invasive Breast Cancer
No recurrences, disease-free survival events, or deaths were reported in select patients with breast cancer who had surgery omitted.